Does Simvastatin Cause More Myotoxicity Compared with Other Statins?

被引:34
作者
Backes, James M. [1 ,2 ]
Howard, Patricia A. [3 ]
Ruisinger, Janelle F. [1 ,2 ]
Moriarty, Patrick M. [2 ]
机构
[1] Univ Kansas, Med Ctr, Dept Pharm Practice, Kansas City, KS 66160 USA
[2] Univ Kansas, Med Ctr, Atherosclerosis & LDL Apheresis Ctr, Kansas City, KS 66160 USA
[3] Univ Kansas, Sch Pharm, Dept Pharm Practice, Kansas City, KS 66160 USA
关键词
drug interactions; myopathy; rhabdomyolysis; statins; ACUTE CORONARY SYNDROMES; HIGH-DOSE ATORVASTATIN; LIPID-LOWERING DRUGS; TRANSPLANT RECIPIENTS; PLASMA-CONCENTRATIONS; GEMFIBROZIL INCREASES; PHARMACOKINETICS; PRAVASTATIN; RHABDOMYOLYSIS; ITRACONAZOLE;
D O I
10.1345/aph.1M410
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
OBJECTIVE: To review the literature regarding statins and myotoxicity and evaluate these data to determine whether incidence rates are higher with simvastatin. DATA SOURCES: Literature was identified from a search of MEDLINE (1966-August 2009) and International Pharmaceutical Abstracts (1970-August 2009), as well as references of selected articles. Key search terms included the names of individual statins, rhabdomyolysis, myopathy, myalgia, myotoxicity, statins, and drug interactions. STUDY SELECTION AND DATA EXTRACTION: All English-language articles discussing statin-related myotoxicity and relevant drug interactions that involved human subjects were examined. DATA SYNTHESIS: Simvastatin is a commonly prescribed, moderately potent statin. Recent evidence suggests that the risk of severe muscle toxicity with simvastatin may be higher than that with other statins, particularly when used in combination with cytochrome P450 isoenzyme inhibitors. However, the lack of direct comparative clinical trials assessing the risk of myotoxicity among the statins in equivalent doses precludes definitive conclusions. Data sources examining low-to-moderate doses of simvastatin suggest that myotoxicity with this agent is infrequent, with rates similar to those seen with other statins. Conversely, findings from clinical trials using the maximum daily dose (80 mg) and a clinical trials database of varying doses of simvastatin suggest a possible increase in rates of myotoxicity with the 80-mg dose compared with lower doses and a higher incidence rate when compared with maximum doses of other statins. CONCLUSIONS: Overall, the rates of severe myotoxicity with all statins are low, especially with low-to-moderate doses. However, recent trials for those using simvastatin 80 mg daily suggest a higher incidence of myotoxicity compared with maximum approved doses of other statins. Practitioners should be aware of these possible risks and individualize therapy to limit myotoxicity.
引用
收藏
页码:2012 / 2020
页数:9
相关论文
共 73 条
[1]
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[2]
A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers [J].
Amsden, GW ;
Kuye, O ;
Wei, GCG .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04) :444-449
[3]
PLASMA-CONCENTRATION PROFILES OF SIMVASTATIN 3-HYDROXY-3-METHYL-GLUTARYL-COENZYME-A REDUCTASE INHIBITORY ACTIVITY IN KIDNEY-TRANSPLANT RECIPIENTS WITH AND WITHOUT CYCLOSPORINE [J].
ARNADOTTIR, M ;
ERIKSSON, LO ;
THYSELL, H ;
KARKAS, JD .
NEPHRON, 1993, 65 (03) :410-413
[4]
Åsberg A, 2003, DRUGS, V63, P367
[5]
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites [J].
Backman, JT ;
Lulurila, H ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :154-167
[6]
Plasma concentrations of active simvastatin acid are increased by gemfibrozil [J].
Backman, JT ;
Kyrklund, C ;
Kivistö, KT ;
Wang, JS ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :122-129
[7]
Statin safety: An overview and assessment of the data-2005 [J].
Bays, H .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :6C-26C
[8]
Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics [J].
Becquemont, L. ;
Neuvonen, M. ;
Verstuyft, C. ;
Jaillon, P. ;
Letierce, A. ;
Neuvonen, P. J. ;
Funck-Brentano, C. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) :679-684
[9]
Etiology and frequency of rhabdomyolysis [J].
Black, C ;
Jick, H .
PHARMACOTHERAPY, 2002, 22 (12) :1524-1526
[10]
Statin safety and drug interactions: Clinical implications [J].
Bottorff, MB .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :27C-31C